Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virucidal activity of oral antiseptics against respiratory viruses
2024-515939-30-01Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Start
- Apr 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of povidone-iodine, Foret and Mucomel in respiratory virus infection (RTI) (3 arms), sponsored by Instituto de Investigación Sanitaria de Santiago de Compostela. Primary endpoints: Change in salivary viral load over time after mouthwash application and Proportion of intact viral particles by I/T ratio. Planned start Apr 2025; status: authorised.
02
Drugs
povidone-iodineForetMucomel
03
Conditions
respiratory virus infection (RTI)
Beyond the preview
Go deeper on 2024-515939-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515939-30-01.